Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 225

Similar articles for PubMed (Select 21936928)

1.

Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia.

Aljunid S, Abuduxike G, Ahmed Z, Sulong S, Nur AM, Goh A.

BMC Infect Dis. 2011 Sep 21;11:248. doi: 10.1186/1471-2334-11-248.

2.

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.

Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS.

Vaccine. 2011 Sep 2;29(38):6686-94. doi: 10.1016/j.vaccine.2011.06.091. Epub 2011 Jul 13.

PMID:
21745516
3.

Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.

Sohn HS, Suh DC, Jang E, Kwon JW.

J Manag Care Pharm. 2010 Jan-Feb;16(1):32-45.

4.

A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.

Asensi F, De Jose M, Lorente M, Moraga F, Ciuryla V, Arikian S, Casciano R, Vento M.

Value Health. 2004 Jan-Feb;7(1):36-51.

PMID:
14720129
5.

Economic evaluation of pneumococcal conjugate vaccination in The Gambia.

Kim SY, Lee G, Goldie SJ.

BMC Infect Dis. 2010 Sep 3;10:260. doi: 10.1186/1471-2334-10-260.

6.

Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).

Díez-Domingo J, Ridao-López M, Gutiérrez-Gimeno MV, Puig-Barberá J, Lluch-Rodrigo JA, Pastor-Villalba E.

Vaccine. 2011 Dec 6;29(52):9640-8. doi: 10.1016/j.vaccine.2011.10.038. Epub 2011 Oct 24.

PMID:
22027484
7.

Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.

Melegaro A, Edmunds WJ.

Vaccine. 2004 Oct 22;22(31-32):4203-14.

PMID:
15474710
8.

Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland.

Tilson L, Usher C, Butler K, Fitzsimons J, O'Hare F, Cotter S, O'Flanagan D, Johnson H, Barry M.

Value Health. 2008 Sep-Oct;11(5):898-903. doi: 10.1111/j.1524-4733.2008.00341.x. Epub 2008 May 16.

PMID:
18489504
9.

Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina.

Giglio ND, Cane AD, Micone P, Gentile A.

Vaccine. 2010 Mar 8;28(11):2302-10. doi: 10.1016/j.vaccine.2009.12.070. Epub 2010 Jan 9.

PMID:
20064478
10.
11.

Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.

Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR.

Clin Ther. 2013 Feb;35(2):119-34. doi: 10.1016/j.clinthera.2012.12.006. Epub 2013 Jan 10.

PMID:
23312274
12.

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland.

Blank PR, Szucs TD.

Vaccine. 2012 Jun 13;30(28):4267-75. doi: 10.1016/j.vaccine.2012.04.028. Epub 2012 Apr 20.

PMID:
22521287
13.

The cost-effectiveness of pneumococcal conjugate vaccination in Australia.

Butler JR, McIntyre P, MacIntyre CR, Gilmour R, Howarth AL, Sander B.

Vaccine. 2004 Mar 12;22(9-10):1138-49.

PMID:
15003641
14.

Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.

Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, Rodenburg GD, Hak E, Postma MJ.

BMJ. 2010 Jun 2;340:c2509. doi: 10.1136/bmj.c2509.

15.

Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic.

Rubin JL, McGarry LJ, Klugman KP, Strutton DR, Gilmore KE, Weinstein MC.

BMC Infect Dis. 2010 Jan 21;10:14. doi: 10.1186/1471-2334-10-14.

16.

Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.

Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS.

Vaccine. 2006 Jul 17;24(29-30):5690-9. Epub 2006 May 5.

PMID:
16735083
17.

Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis.

Rozenbaum MH, van Hoek AJ, Fleming D, Trotter CL, Miller E, Edmunds WJ.

BMJ. 2012 Oct 26;345:e6879. doi: 10.1136/bmj.e6879.

18.

The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine.

Silfverdal SA, Berg S, Hemlin C, Jokinen I.

Vaccine. 2009 Mar 4;27(10):1601-8. doi: 10.1016/j.vaccine.2008.12.033. Epub 2009 Jan 13.

PMID:
19146905
19.

Economic evaluation of universal 7-valent pneumococcal conjugate vaccination in Taiwan: a cost-effectiveness analysis.

Wu DB, Rinaldi F, Huang YC, Chang JA, Chang CJ.

J Formos Med Assoc. 2013 Mar;112(3):151-60. doi: 10.1016/j.jfma.2011.10.006. Epub 2012 May 9.

PMID:
23473528
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk